According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
A number of other research analysts have also issued reports on the stock. ValuEngine raised shares of Omeros from a hold rating to a buy rating in a research note on Tuesday, January 15th. HC Wainwright reissued a buy rating and set a $35.00 target price on shares of Omeros in a research note on Monday, March 4th. Finally, Cantor Fitzgerald started coverage on shares of Omeros in a research note on Monday, May 6th. They set an overweight rating and a $26.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $26.83.
Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The business had revenue of $21.80 million for the quarter, compared to analysts’ expectations of $23.18 million. The firm’s revenue for the quarter was up 1271.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.62) earnings per share. Analysts anticipate that Omeros will post -0.63 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in shares of Omeros by 73.3% in the 4th quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock worth $805,000 after acquiring an additional 30,547 shares during the period. Man Group plc acquired a new stake in shares of Omeros in the 3rd quarter worth approximately $286,000. Miramar Capital LLC acquired a new stake in shares of Omeros in the 4th quarter worth approximately $192,000. Quad Cities Investment Group LLC lifted its stake in shares of Omeros by 28.2% in the 1st quarter. Quad Cities Investment Group LLC now owns 13,650 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 3,000 shares during the period. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in shares of Omeros by 8.8% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 24,750 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 2,000 shares during the period. 49.49% of the stock is owned by institutional investors.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: What is the price-sales ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.